ICD-10 Coding for Transaminitis Secondary to Rosuvastatin(E78.00U, K71.9, K71.9B)
Learn about the ICD-10 coding for transaminitis secondary to rosuvastatin, including documentation requirements and coding pitfalls.
Complete code families applicable to Transaminitis Secondary to Rosuvastatin
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| T46.6X5A | Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | Use when there is a documented adverse effect of rosuvastatin causing liver enzyme elevation. |
|
| K71.9 | Toxic liver disease, unspecified | Use when there is confirmed drug-induced liver injury without specific etiology. |
|
| R74.01 | Elevation of levels of liver transaminases and lactic acid dehydrogenase [LDH] | Use when there is an elevation of liver enzymes without a specific diagnosis of liver disease. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutTransaminitis Secondary to Rosuvastatin
Alternative codes to consider when ruling out similar conditions
Use for accidental overdose rather than adverse effect.
Use when the cause of liver inflammation is not identified as drug-induced.
Documentation & Coding Risks
Avoid these common issues when documenting Transaminitis Secondary to Rosuvastatin.
Failure to document drug as cause of liver injury
Impact
Clinical: May lead to misdiagnosis and inappropriate treatment., Regulatory: Non-compliance with coding standards., Financial: Potential for denied claims or reduced reimbursement.
Mitigation
Ensure documentation explicitly states drug as cause., Use templates to guide documentation.
Using R74.01 without T46.6X5A
Impact
Reimbursement: May lead to lower reimbursement due to incomplete coding., Compliance: Non-compliance with ICD-10 coding guidelines., Data Quality: Inaccurate representation of the patient's condition.
Mitigation
Always pair R74.01 with T46.6X5A for adverse drug reactions.
Coding 'statin intolerance' instead of DILI
Impact
Reimbursement: Incorrect coding may affect DRG assignment., Compliance: Misrepresentation of the patient's condition., Data Quality: Inaccurate clinical data for research and analysis.
Mitigation
Use T46.6X5A for adverse effects, not Z91.14 for intolerance.
Incomplete coding of drug-induced liver injury
Impact
Failure to use both adverse effect and liver condition codes.
Mitigation
Implement coding audits and education on proper code combinations.
Frequently Asked Questions
Primary Code
Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter5AToxic liver disease, unspecifie